New NCCN Guidelines: Recognition and Management of Immunotherapy-Related Toxicity
- PMID: 29784734
- DOI: 10.6004/jnccn.2018.0047
New NCCN Guidelines: Recognition and Management of Immunotherapy-Related Toxicity
Abstract
Immune checkpoint inhibitors (ICIs) are now FDA-approved for the treatment of 8 different cancers, and more approvals are likely, including use of these drugs in combinations. Although ICIs represent a true advance in cancer care, they can cause a range of immune-related adverse events. As more experience with ICIs is gained, more information is becoming available on immunotoxicity and optimal management. Physicians and patients need to be educated about potential adverse events and management of ICI-associated toxicity. In recognition of the need for better information, NCCN in collaboration with ASCO has developed the first set of NCCN Guidelines for Management of Immunotherapy-Related Toxicities.
Copyright © 2018 by the National Comprehensive Cancer Network.
Similar articles
-
Management of Immunotherapy-Related Toxicities, Version 1.2019.J Natl Compr Canc Netw. 2019 Mar 1;17(3):255-289. doi: 10.6004/jnccn.2019.0013. J Natl Compr Canc Netw. 2019. PMID: 30865922
-
Endocrine dysfunction induced by immune checkpoint inhibitors: Practical recommendations for diagnosis and clinical management.Cancer. 2018 Mar 15;124(6):1111-1121. doi: 10.1002/cncr.31200. Epub 2018 Jan 3. Cancer. 2018. PMID: 29313945 Review.
-
A Multidisciplinary Toxicity Team for Cancer Immunotherapy-Related Adverse Events.J Natl Compr Canc Netw. 2019 Jun 1;17(6):712-720. doi: 10.6004/jnccn.2018.7268. J Natl Compr Canc Netw. 2019. PMID: 31200355
-
Endocrine toxicity of immune checkpoint inhibitors: a real-world study leveraging US Food and Drug Administration adverse events reporting system.J Immunother Cancer. 2019 Nov 6;7(1):286. doi: 10.1186/s40425-019-0754-2. J Immunother Cancer. 2019. PMID: 31694698 Free PMC article.
-
Management of immunotherapy toxicities in older adults.Semin Oncol. 2018 Aug;45(4):226-231. doi: 10.1053/j.seminoncol.2018.09.001. Epub 2018 Nov 13. Semin Oncol. 2018. PMID: 30446167 Review.
Cited by
-
PD-1/PD-L1 immune checkpoint inhibitors in glioblastoma: clinical studies, challenges and potential.Hum Vaccin Immunother. 2021 Feb 1;17(2):546-553. doi: 10.1080/21645515.2020.1782692. Epub 2020 Jul 9. Hum Vaccin Immunother. 2021. PMID: 32643507 Free PMC article. Review.
-
Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation.J Hematol Oncol. 2022 Mar 12;15(1):24. doi: 10.1186/s13045-022-01242-2. J Hematol Oncol. 2022. PMID: 35279217 Free PMC article. Review.
-
The current landscape of immunotherapy for pediatric brain tumors.Nat Cancer. 2022 Jan;3(1):11-24. doi: 10.1038/s43018-021-00319-0. Epub 2022 Jan 20. Nat Cancer. 2022. PMID: 35121998 Review.
-
Immune-related aseptic meningitis and strategies to manage immune checkpoint inhibitor therapy: a systematic review.J Neurooncol. 2022 May;157(3):533-550. doi: 10.1007/s11060-022-03997-7. Epub 2022 Apr 13. J Neurooncol. 2022. PMID: 35416575 Free PMC article. Review.
-
Concurrent therapy with immune checkpoint inhibitors and TNFα blockade in patients with gastrointestinal immune-related adverse events.J Immunother Cancer. 2019 Aug 22;7(1):226. doi: 10.1186/s40425-019-0711-0. J Immunother Cancer. 2019. PMID: 31439050 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
